Gathering consensus on mHSPC Treatment

Welcome to our dedicated resource on the

and the

APCCC 2024 Publication

, which provide essential clinical guidance on the optimal treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC).

These publications represent the collaborative efforts of leading healthcare professionals in the field, focusing on the most effective approaches to managing mHSPC. They offer valuable insights into who should be considered for triplet therapy, specifically the combination of darolutamide, androgen deprivation therapy (ADT), and docetaxel.

By establishing clear recommendations, the consensus aims to enhance clinical decision-making and improve patient outcomes.

Please find below, an infographic that summarises the key points from both the UK Modified Delphi Consensus and the APCCC 2024, illustrating the findings and recommendations from these important publications.